Enwei Pharmaceutical released its 2026 interim report. Total operating revenue was 375 million yuan, down 16.62% year-on-year. Net profit attributable to the parent company was 16.0229 million yuan, down 58.21% from the same period last year. Net cash inflow from operating activities was 66.0645 million yuan, down 12.13% year-on-year. The company's asset-liability ratio was 28.92%, gross margin was 51.18%, and diluted earnings per share was 0.16 yuan, down 59.51% year-on-year. The number of shareholders was 6,714, and the top ten shareholders held 69.42% of the shares.
Enwei Pharmaceutical Co. Ltd. A2026 interim report shows net profit down 58.21% YoY and revenue down 16.62% YoY.
